Abstract
Introduction/BackgroundTo decrease immunosuppression and enhance T-cell activation in the tumour microenvironment, we conducted an open-label, investigator-initiated, multicohort, phase II trial (NCT03192059) of pembrolizumab with multimodal immunomodulation.MethodologyChemotherapy-pretreated patients were recruited into...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have